Full Press Release Details
Announces the Appointment of Jeffrey Janus as Vice President
senior executive with significant experience in sales and marketing of
ALAMEDA, Calif.--(BUSINESS WIRE)--December 20, 2012--BioTime, Inc. (NYSE
MKT: BTX) today announced the appointment of Jeffrey Janus as its Vice
President of Sales and Marketing. Mr. Janus' primary focus will be to
create, market, and sell research products for BioTime and its
subsidiaries in the expanding field of regenerative medicine. Mr. Janus
has more than 25 years of experience and a proven track record of
creating profitable commercial cell-based business.
"Jeffrey brings tremendous expertise in regenerative medicine,
developing and selling research products and reagents, and building
business units," said Michael D. West, PhD, BioTime's Chief Executive
Officer. "We welcome Jeffrey to the BioTime team and look forward to
working together with him in expanding our development, marketing, and
sale of research products."
"I am honored and excited to be a part of the BioTime team. It is
especially gratifying to be working with BioTime's partner LifeMap
Sciences, Inc. and their unique and powerful on-line integrated database
suite for genomic, biomedical and stem cell research. This in-depth
database suite, linked to BioTime's unique PureStem lines
of standardized human progenitor cells, gives researchers a
comprehensive set of tools to study human embryonic development and stem
cell biology. Medical research has always depended upon the availability
of standardized research products and information, and BioTime and
LifeMap have become leaders in consolidating biomedical information with
standardized stem cells."
Mr. Janus was most recently Senior Vice President of Operations at
International Stem Cell Corporation (OTCQB: ISCO), where he led the
company to discover a process known as parthenogenesis resulting
in functional human pluripotent stem cells without the use of fertilized
human embryos, and was previously the CEO and founder of Lifeline Cell
Technology, LLC, a subsidiary of ISCO. Prior to that, he was a member of
the founding team that created Clonetics Corporation and the Clonetics
brand of primary human cell products. In addition to his extensive
experience in developing and selling cell-based products to the research
market, Mr. Janus has led teams of scientists both internally and
through external domestic and international collaborations with major
academic institutions to conduct research. He has grown several
biotechnology companies from the ground up, from licensing or patenting
intellectual property, to building teams to develop, manufacture and
market products profitably. He has a deep understanding of the process
of creating and managing teams and has used the strategic planning
process to great success.
Mr. Janus has a Masters Degree in Business Administration from
California State University, San Diego and a Bachelor Degree in
Biochemistry from the University of California at Davis and is a
published author of breakthrough papers in the field of parthenogenesis
and stem cell research.
BioTime, headquartered in Alameda, Calif., is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its
broad platform of stem cell technologies is enhanced through
subsidiaries focused on specific fields of application. BioTime develops
and markets research products in the fields of stem cells and
regenerative medicine, including a wide array of proprietary PureStem
cell lines, HyStem hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia (formerly
known as HyStem -Rx), a biocompatible,
implantable hyaluronan and collagen-based matrix for cell delivery in
human clinical applications. BioTime's therapeutic product development
strategy is pursued through subsidiaries that focus on specific organ
systems and related diseases for which there is a high unmet medical
need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the
treatment of retinal and neural degenerative diseases. BioTime's
subsidiary OrthoCyte Corporation is developing therapeutic applications
of stem cells to treat orthopedic diseases and injuries. Another
subsidiary, OncoCyte Corporation, focuses on the diagnostic and
therapeutic applications of stem cell technology in cancer, including
the diagnostic product PanC-Dx currently being developed for the
detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent
stem cell technology to reverse the developmental aging of human cells
to treat cardiovascular and blood cell diseases. BioTime's subsidiary
LifeMap Sciences, Inc., markets GeneCards , the
leading human gene database, and has developed an integrated database
suite to complement GeneCards that includes the LifeMap
Discovery database of embryonic development, stem cell research and
regenerative medicine, and MalaCards, the human disease database.
LifeMap is also marketing BioTime research products. BioTime's lead
product, Hextend , is a blood plasma volume
expander manufactured and distributed in the U.S. by Hospira, Inc., and
in South Korea by CJ CheilJedang Corporation under exclusive licensing
agreements. Additional information about BioTime can be found on the web
Forward-Looking Statements
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates") should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such